Clinical Trial Halt Sends Intellia Shares into Turmoil
Investors in Intellia Therapeutics are bracing for impact as the biotech firm faces one of its most significant challenges to date. While third-quarter earnings are…
Breaking news and expert insights on markets, stocks, and cryptocurrencies